Ticker LaunchIPO · CVKD
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. (CVKD) priced its initial public offering on Jan 23, 2023 at $5.00 per share, raising $7M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $58.2M. Boustead was lead-left underwriter, joined by Sutter and Revere. Blank Rome advised the company and Michelman & Robinson advised the underwriters.
Cadrenal Therapeutics, Inc. is developing tecarfarin, a therapy with orphan drug designation for preventing blood clots of cardiac origin in patients with end-stage renal disease and atrial fibrillation. It obtained rights to tecarfarin in April 2022 through an asset purchase.
- Status
- IPO
- Ticker
- CVKD
- Exchange
- Nasdaq Capital Market
- Priced
- Jan 23, 2023
- IPO price
- $5.00
- Raised
- $7M
- Market cap at IPO price
- $58.2M
- First filed
- Sep 22, 2022
- Company counsel
- Blank Rome
- Underwriters' counsel
- Michelman & Robinson
- Sector
- Biotech & pharma
- Country / state
- FL
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Sep 22, 2022
- Latest amendment Jan 17, 2023
- Final prospectus (424B4) Jan 23, 2023
- All filings on EDGAR CIK 1937993
Other Biotech & pharma IPOs in 2023
- CytoMed Therapeutics LtdGDTC · Apr 17, 2023 · $9.6M
- BullFrog AI Holdings, Inc.BFRG · Feb 16, 2023 · $8.4M
- Lucy Scientific Discovery, Inc.LSDI · Feb 10, 2023 · $7.5M
- Mineralys Therapeutics, Inc.MLYS · Feb 10, 2023 · $192M
- Structure Therapeutics Inc.GPCR · Feb 6, 2023 · $161.1M
- GENELUX CorpGNLX · Jan 26, 2023 · $15M